Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
25/26-hydroxycholesterol 7alpha-hydroxylase deficiency
Mechanisms of disease: Inborn errors of bile acid synthesis.
Acquired Immunodeficiency Syndrome
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Acquired Immunodeficiency Syndrome
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
Adenocarcinoma
34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts.
Adenocarcinoma
?-Methylacyl-CoA Racemase (AMACR) in Gastric Cancer: Correlation With Clinicopathologic Data and Disease-free Survival.
Adenocarcinoma
A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Adenocarcinoma
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
Adenocarcinoma
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Adenocarcinoma
Abundant expression of AMACR in many distinct tumour types.
Adenocarcinoma
Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: Is AMACR a "race"-dependent marker?
Adenocarcinoma
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Adenocarcinoma
Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate.
Adenocarcinoma
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Adenocarcinoma
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Adenocarcinoma
Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Adenocarcinoma
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Adenocarcinoma
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Adenocarcinoma
Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
Adenocarcinoma
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Adenocarcinoma
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
Adenocarcinoma
Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report.
Adenocarcinoma
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Adenocarcinoma
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Adenocarcinoma
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Adenocarcinoma
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Adenocarcinoma
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Adenocarcinoma
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Adenocarcinoma
Cytokeratin (AE1/AE3) in addition to alpha-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma.
Adenocarcinoma
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Adenocarcinoma
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Adenocarcinoma
Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
Adenocarcinoma
Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.
Adenocarcinoma
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Adenocarcinoma
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Adenocarcinoma
Expression of Alpha Methylacyl CoA Racemase (AMACR) in Gastric Adenocarcinoma and Its Correlation with Helicobacter pylori Infection.
Adenocarcinoma
Expression of alpha-methylacyl coenzyme A racemase in partial and complete focal atrophy on prostate needle biopsies.
Adenocarcinoma
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Adenocarcinoma
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Adenocarcinoma
Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Adenocarcinoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Adenocarcinoma
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Adenocarcinoma
Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
Adenocarcinoma
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Adenocarcinoma
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Adenocarcinoma
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Adenocarcinoma
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Adenocarcinoma
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
Adenocarcinoma
Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Adenocarcinoma
Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Adenocarcinoma
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Adenocarcinoma
Intestinal, intestinal-type and intestine-localized metastatic adenocarcinoma. Immunohistochemical approach to the differential diagnosis.
Adenocarcinoma
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Adenocarcinoma
Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
Adenocarcinoma
MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR.
Adenocarcinoma
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
Adenocarcinoma
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.
Adenocarcinoma
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Adenocarcinoma
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
Adenocarcinoma
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Adenocarcinoma
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Adenocarcinoma
Performance comparison of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody vs. Monoclonal Rabbit Anti-Human AMACR clone 13H4 when duplexed with VENTANA Basal Cell Cocktail (34?E12+p63) as a diagnostic aid for prostatic adenocarcinoma using immunohistochemistry.
Adenocarcinoma
Primary prostate cancer synchronous with renal cell carcinoma: clinical experience and literature review.
Adenocarcinoma
Primary seminal vesicle adenocarcinoma: A case report of rare entity and discussion of its differential diagnosis using immunohistochemical approach for the core biopsy specimen.
Adenocarcinoma
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Adenocarcinoma
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Adenocarcinoma
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Adenocarcinoma
Reliability of the 34betaE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Adenocarcinoma
Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
Adenocarcinoma
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Adenocarcinoma
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Adenocarcinoma
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Adenocarcinoma
Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
Adenocarcinoma
Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
Adenocarcinoma
The expressions of AMACR and iNOS in prostate adenocarcinomas.
Adenocarcinoma
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Adenocarcinoma
Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
Adenocarcinoma
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Adenocarcinoma
Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.
Adenocarcinoma
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Adenocarcinoma
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Adenocarcinoma
Variation of alpha-methylacyl-CoA racemase expression in prostate adenocarcinoma cases receiving hormonal therapy.
Adenocarcinoma
What's new in prostate cancer disease assessment in 2006?
Adenocarcinoma
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
Adenocarcinoma
[Assessment of P504S immunohistochemistry in diagnosis and differential diagnosis of prostatic adenocarcinoma.]
Adenocarcinoma
[Detection of P504S (alpha-methylacyl-CoA racemase) in prostatic adenocarcinomas]
Adenocarcinoma
[Estimation of the diagnostic potential of APOD, PTOV1, and EPHA4 for prostatic neoplasms].
Adenocarcinoma
[Fatty acid synthase in the diagnosis of prostate neoplasms].
Adenocarcinoma
[Histopathological features of prostate cancer]
Adenocarcinoma
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
Adenocarcinoma of Lung
Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Adenocarcinoma, Clear Cell
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Adenoma
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Adenoma
Abundant expression of AMACR in many distinct tumour types.
Adenoma
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Adenoma
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Adenoma
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.
Adenoma
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
Adenoma
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Adenoma
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Adenoma
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Adenoma
Differential expression of p53 and p504s in hyperplastic polyp, sessile serrated adenoma and traditional serrated adenoma.
Adenoma
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma.
Adenoma
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Adenoma
Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Adenoma
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Adenoma
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Adenoma
Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry.
Adenoma
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
Adenoma
Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.
Adenoma
Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics.
Adenoma
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Adenoma
Nephrogenic adenomas in pediatric patients: a morphologic and immunohistochemical study of 21 cases.
Adenoma
Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
Adenoma
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Adenoma
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Adenoma, Liver Cell
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Adenoma, Oxyphilic
Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Adenoma, Oxyphilic
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Adenoma, Oxyphilic
Papillary renal cell carcinoma embedded in an oncocytoma: Case report of a rare combined tumour of the kidney.
Adenoma, Villous
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.
Adenoma, Villous
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Adenomatous Polyposis Coli
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Adrenoleukodystrophy
Clinical consequences of defects in peroxisomal beta-oxidation.
Albinism, Oculocutaneous
Incidental finding of alpha-methylacyl-CoA racemase deficiency in a patient with oculocutaneous albinism type 4.
alpha-methylacyl-coa racemase deficiency
A mouse model for alpha-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids.
alpha-methylacyl-coa racemase deficiency
Alpha methyl acyl CoA racemase deficiency: Diagnosis with isolated elevated liver enzymes.
alpha-methylacyl-coa racemase deficiency
An adult onset case of alpha-methyl-acyl-CoA racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Clinical consequences of defects in peroxisomal beta-oxidation.
alpha-methylacyl-coa racemase deficiency
Episodic hyperCKaemia may be a feature of ?-methylacyl-coenzyme A racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency.
alpha-methylacyl-coa racemase deficiency
Incidental finding of alpha-methylacyl-CoA racemase deficiency in a patient with oculocutaneous albinism type 4.
alpha-methylacyl-coa racemase deficiency
Mechanisms of disease: Inborn errors of bile acid synthesis.
alpha-methylacyl-coa racemase deficiency
MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing.
alpha-methylacyl-coa racemase deficiency
Phytol is lethal for Amacr-deficient mice.
alpha-methylacyl-coa racemase deficiency
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
alpha-methylacyl-coa racemase deficiency
Reinvestigation of peroxisomal 3-ketoacyl-CoA thiolase deficiency: identification of the true defect at the level of d-bifunctional protein.
alpha-methylacyl-coa racemase deficiency
Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency.
alpha-methylacyl-coa racemase deficiency
Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
alpha-methylacyl-coa racemase deficiency
Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.
alpha-methylacyl-coa racemase deficiency
The influence of the branched-chain fatty acids pristanic acid and Refsum disease-associated phytanic acid on mitochondrial functions and calcium regulation of hippocampal neurons, astrocytes, and oligodendrocytes.
alpha-methylacyl-coa racemase deficiency
Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency.
Angiomyolipoma
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Arthritis
Impaired intrinsic chiral inversion activity of ibuprofen in rats with adjuvant-induced arthritis.
Barrett Esophagus
A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Barrett Esophagus
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Barrett Esophagus
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Barrett Esophagus
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Barrett Esophagus
p16, Cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
Brain Diseases
Phytol is lethal for Amacr-deficient mice.
Brain Diseases
Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.
Brain Neoplasms
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Breast Diseases
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
Breast Neoplasms
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Breast Neoplasms
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Breast Neoplasms
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Carcinogenesis
A statistical method for identifying differential gene-gene co-expression patterns.
Carcinogenesis
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Carcinogenesis
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Carcinogenesis
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Carcinogenesis
Chromosome 5p Region SNPs Are Associated with Risk of NSCLC among Women.
Carcinogenesis
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Carcinogenesis
Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
Carcinogenesis
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Carcinogenesis
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Carcinogenesis
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Carcinogenesis
High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.
Carcinogenesis
Human prostate cancer precursors and pathobiology.
Carcinogenesis
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Carcinogenesis
Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane.
Carcinogenesis
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Carcinoid Tumor
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Carcinoma
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Carcinoma
?-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
Carcinoma
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Carcinoma
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
Carcinoma
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Carcinoma
Abundant expression of AMACR in many distinct tumour types.
Carcinoma
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Carcinoma
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Carcinoma
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Carcinoma
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Carcinoma
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Carcinoma
Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate.
Carcinoma
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Carcinoma
Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.
Carcinoma
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Carcinoma
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Carcinoma
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Carcinoma
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Carcinoma
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Carcinoma
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Carcinoma
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Carcinoma
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Carcinoma
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Carcinoma
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Carcinoma
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Carcinoma
Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
Carcinoma
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
Carcinoma
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
Carcinoma
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Carcinoma
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Carcinoma
Atypical Renal Cysts: A Morphologic, Immunohistochemical, and Molecular Study.
Carcinoma
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Carcinoma
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
Carcinoma
CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Carcinoma
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Carcinoma
Clear cell papillary renal cell carcinoma: a case report and literature review.
Carcinoma
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Carcinoma
Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
Carcinoma
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Carcinoma
Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis.
Carcinoma
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Carcinoma
Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma.
Carcinoma
Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
Carcinoma
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Carcinoma
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Carcinoma
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Carcinoma
Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.
Carcinoma
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Carcinoma
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Carcinoma
Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm.
Carcinoma
Diagnostic Value of Cytokeratin 34 beta E12 (Ck34?E12) and ?-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions.
Carcinoma
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Carcinoma
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Carcinoma
Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Carcinoma
Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.
Carcinoma
Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Carcinoma
Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.
Carcinoma
Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions.
Carcinoma
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Carcinoma
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Carcinoma
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Carcinoma
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Carcinoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Carcinoma
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Carcinoma
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Carcinoma
Foamy gland carcinoma in core needle biopsies of the prostate: clinicopathologic and immunohistochemical study of 56 cases.
Carcinoma
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
Carcinoma
GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma.
Carcinoma
Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Carcinoma
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Carcinoma
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Carcinoma
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Carcinoma
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Carcinoma
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Carcinoma
Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.
Carcinoma
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Carcinoma
Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.
Carcinoma
Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
Carcinoma
Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Carcinoma
In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.
Carcinoma
Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
Carcinoma
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Carcinoma
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Carcinoma
Lymphoepithelioma-like carcinoma of the prostate.
Carcinoma
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.
Carcinoma
Napsin-A and AMACR are Superior to HNF-1? in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.
Carcinoma
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Carcinoma
p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature.
Carcinoma
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Carcinoma
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Carcinoma
P504S: a new molecular marker for the detection of prostate carcinoma.
Carcinoma
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Carcinoma
Phase-Regulated Sensing Mechanism of MoS2 Based Nanohybrids toward Point-of-Care Prostate Cancer Diagnosis.
Carcinoma
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
Carcinoma
Profiling and classification tree applied to renal epithelial tumours.
Carcinoma
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Carcinoma
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Carcinoma
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Carcinoma
Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Carcinoma
Recent advances of immunohistochemistry for diagnosis of renal tumors.
Carcinoma
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Carcinoma
Reliability of the 34betaE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Carcinoma
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study.
Carcinoma
Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis.
Carcinoma
Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.
Carcinoma
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study.
Carcinoma
Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
Carcinoma
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Carcinoma
Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy.
Carcinoma
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Carcinoma
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Carcinoma
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Carcinoma
Tubulocystic renal cell carcinoma: Report of a rare case.
Carcinoma
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Carcinoma
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Carcinoma
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Carcinoma
Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.
Carcinoma
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Carcinoma
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Carcinoma
Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores.
Carcinoma
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Carcinoma
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Carcinoma
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
Carcinoma
[Alpha-methylacyl-CoA racemase: a useful marker for diagnosis of prostatic carcinoma.]
Carcinoma
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
Carcinoma
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
Carcinoma
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
Carcinoma
[Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S]
Carcinoma
[Metastatic renal cell carcinoma: a clinicopathological analysis of 196 cases].
Carcinoma
[Sensitivity and specificity of AMACR expression in diagnosis of prostatic carcinoma]
Carcinoma
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
Carcinoma
[The value of alpha-methylacyl-CoA racemase expression in the progression of colonic carcinoma].
Carcinoma
[Tubulocystic carcinoma of the kidney].
Carcinoma in Situ
CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Carcinoma, Acinar Cell
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Carcinoma, Acinar Cell
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
Carcinoma, Acinar Cell
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Carcinoma, Basal Cell
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Carcinoma, Basal Cell
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma, Ductal
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Carcinoma, Endometrioid
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Carcinoma, Endometrioid
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Carcinoma, Hepatocellular
Abundant expression of AMACR in many distinct tumour types.
Carcinoma, Hepatocellular
Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.
Carcinoma, Hepatocellular
AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma, Hepatocellular
Overexpression of ?-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas.
Carcinoma, Hepatocellular
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Carcinoma, Intraductal, Noninfiltrating
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia.
Carcinoma, Intraductal, Noninfiltrating
[Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].
Carcinoma, Medullary
Cadherin-17 and SATB2 Are Sensitive and Specific Immunomarkers for Medullary Carcinoma of the Large Intestine.
Carcinoma, Neuroendocrine
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Carcinoma, Neuroendocrine
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Carcinoma, Neuroendocrine
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma, Neuroendocrine
Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Carcinoma, Ovarian Epithelial
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Carcinoma, Papillary
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Carcinoma, Papillary
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Carcinoma, Renal Cell
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
Carcinoma, Renal Cell
Abundant expression of AMACR in many distinct tumour types.
Carcinoma, Renal Cell
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Carcinoma, Renal Cell
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Carcinoma, Renal Cell
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Carcinoma, Renal Cell
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Carcinoma, Renal Cell
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Carcinoma, Renal Cell
Atypical Renal Cysts: A Morphologic, Immunohistochemical, and Molecular Study.
Carcinoma, Renal Cell
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Carcinoma, Renal Cell
Clear cell papillary renal cell carcinoma: a case report and literature review.
Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
Carcinoma, Renal Cell
Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis.
Carcinoma, Renal Cell
Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Carcinoma, Renal Cell
Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.
Carcinoma, Renal Cell
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma, Renal Cell
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Carcinoma, Renal Cell
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Carcinoma, Renal Cell
Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Carcinoma, Renal Cell
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Carcinoma, Renal Cell
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Carcinoma, Renal Cell
Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.
Carcinoma, Renal Cell
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Carcinoma, Renal Cell
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Carcinoma, Renal Cell
Profiling and classification tree applied to renal epithelial tumours.
Carcinoma, Renal Cell
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Carcinoma, Renal Cell
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study.
Carcinoma, Renal Cell
Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis.
Carcinoma, Renal Cell
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study.
Carcinoma, Renal Cell
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Carcinoma, Renal Cell
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Carcinoma, Renal Cell
Tubulocystic renal cell carcinoma: Report of a rare case.
Carcinoma, Renal Cell
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Carcinoma, Renal Cell
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
Carcinoma, Renal Cell
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
Carcinoma, Renal Cell
[Metastatic renal cell carcinoma: a clinicopathological analysis of 196 cases].
Carcinoma, Squamous Cell
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Carcinoma, Squamous Cell
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Carcinoma, Squamous Cell
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Cerebellar Ataxia
AMACR mutations cause late-onset autosomal recessive cerebellar ataxia.
Charcot-Marie-Tooth Disease
Role of Alpha-methylacyl-CoA racemase gene in pathogenecity of CMT patients.
Cholelithiasis
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Chondroma
Biomarkers of chondrosarcoma.
Chondrosarcoma
?-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas.
Chondrosarcoma
Biomarkers of chondrosarcoma.
Chordoma
?-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas.
Colitis, Ulcerative
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Colitis-Associated Neoplasms
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Colonic Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Colonic Neoplasms
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Colonic Neoplasms
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Colonic Neoplasms
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Colonic Neoplasms
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Colonic Neoplasms
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Colonic Neoplasms
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Colonic Neoplasms
[The value of alpha-methylacyl-CoA racemase expression in the progression of colonic carcinoma].
Colorectal Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Colorectal Neoplasms
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Colorectal Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Colorectal Neoplasms
Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
Colorectal Neoplasms
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Colorectal Neoplasms
AMACR expression in colorectal cancer is associated with left-sided tumor localization.
Colorectal Neoplasms
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Colorectal Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Colorectal Neoplasms
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Colorectal Neoplasms
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Crohn Disease
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Cystadenocarcinoma, Mucinous
Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall.
Cystadenoma, Papillary
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Dysplastic Nevus Syndrome
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Endodermal Sinus Tumor
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Endometrial Neoplasms
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Extranodal Extension
Circulating mRNA Signature as a Marker for High-Risk Prostate Cancer.
Gastrointestinal Stromal Tumors
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Glioblastoma
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Glioma
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Inflammatory Bowel Diseases
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Inflammatory Bowel Diseases
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Kidney Diseases
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Kidney Failure, Chronic
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Kidney Failure, Chronic
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Kidney Neoplasms
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Kidney Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Kidney Neoplasms
Fluorescence in situ hybridization as an adjunct tool in the diagnosis of primary and metastatic renal cell carcinoma in fine needle aspiration specimens.
Kidney Neoplasms
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Kidney Neoplasms
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Liposarcoma, Myxoid
Scattered genomic amplification in dedifferentiated liposarcoma.
Liver Diseases
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.
Liver Neoplasms
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.
Lung Neoplasms
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Lymphoma
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Melanoma
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Melanoma
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Melanoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Melanoma
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Melanoma
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
Mesothelioma
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
Mesothelioma, Malignant
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
Motor Neuron Disease
Characterization of the mutant ?-subunit of ?-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype.
Nasopharyngeal Carcinoma
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Neoplasm Metastasis
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Neoplasm Metastasis
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Neoplasm Metastasis
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Neoplasm Metastasis
An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.
Neoplasm Metastasis
Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.
Neoplasm Metastasis
Endobronchial metastasis from prostate cancer mimicking primary lung cancer.
Neoplasm Metastasis
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Neoplasm Metastasis
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Neoplasms
"Mucin"-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases.
Neoplasms
?-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.
Neoplasms
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
Neoplasms
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Neoplasms
?-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Neoplasms
A Case of a Malignant Cutaneous Mixed Tumor (Chondroid Syringoma) of the Scapula Treated With Staged Margin-Controlled Excision.
Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Neoplasms
A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Neoplasms
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
Neoplasms
A Rare Case of Renal Cell Carcinoma With Leiomyomatous Stroma and Concomitant Ruptured Adrenal Aneurysm.
Neoplasms
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Neoplasms
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
Neoplasms
A statistical method for identifying differential gene-gene co-expression patterns.
Neoplasms
A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.
Neoplasms
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Neoplasms
Abundant expression of AMACR in many distinct tumour types.
Neoplasms
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Neoplasms
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Neoplasms
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Neoplasms
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Neoplasms
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Neoplasms
Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies.
Neoplasms
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Neoplasms
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Neoplasms
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Neoplasms
Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.
Neoplasms
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia.
Neoplasms
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Neoplasms
Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.
Neoplasms
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Neoplasms
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Neoplasms
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Neoplasms
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Neoplasms
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Neoplasms
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Neoplasms
Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage.
Neoplasms
Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
Neoplasms
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Neoplasms
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Neoplasms
Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
Neoplasms
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Neoplasms
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Neoplasms
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer.
Neoplasms
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Neoplasms
AMACR expression in colorectal cancer is associated with left-sided tumor localization.
Neoplasms
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Neoplasms
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
Neoplasms
AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma.
Neoplasms
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
Neoplasms
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Neoplasms
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
Neoplasms
AMACR: an emerging diagnostic and prognostic tool in systemic malignancies.
Neoplasms
An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.
Neoplasms
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Neoplasms
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Neoplasms
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
Neoplasms
Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
Neoplasms
BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Neoplasms
Biphasic squamoid alveolar renal carcinoma with positive CD57 expression: A clinicopathologic study of three cases.
Neoplasms
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Neoplasms
CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis.
Neoplasms
Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.
Neoplasms
Circulating mRNA Signature as a Marker for High-Risk Prostate Cancer.
Neoplasms
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications.
Neoplasms
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Neoplasms
Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study.
Neoplasms
Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma.
Neoplasms
Clear cell papillary renal cell carcinoma: a clinicopathologic analysis of 6 cases.
Neoplasms
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity.
Neoplasms
Clear cell papillary renal cell carcinoma: a review.
Neoplasms
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Neoplasms
Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
Neoplasms
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Neoplasms
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Neoplasms
Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
Neoplasms
Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.
Neoplasms
Combined ?-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells.
Neoplasms
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Neoplasms
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Neoplasms
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Neoplasms
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Neoplasms
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.
Neoplasms
Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Neoplasms
Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
Neoplasms
Current Knowledge on the Function of ?-Methyl Acyl-CoA Racemase in Human Diseases.
Neoplasms
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Neoplasms
Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors.
Neoplasms
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Neoplasms
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Neoplasms
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Neoplasms
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Neoplasms
Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
Neoplasms
Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.
Neoplasms
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Neoplasms
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Neoplasms
Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm.
Neoplasms
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Neoplasms
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Neoplasms
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Neoplasms
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma.
Neoplasms
Ductal adenocarcinoma of the prostate: current opinion and controversies.
Neoplasms
Embryonal Origin of Metanephric Adenoma and its Differential Diagnosis.
Neoplasms
Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions.
Neoplasms
Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Neoplasms
EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma.
Neoplasms
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth.
Neoplasms
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Neoplasms
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Neoplasms
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Neoplasms
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Neoplasms
Expression of genes and proteins specific for prostate cancer.
Neoplasms
Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia.
Neoplasms
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer.
Neoplasms
Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.
Neoplasms
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology.
Neoplasms
EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
Neoplasms
Fine needle aspiration biopsy of renal mucinous tubular and spindle cell carcinoma: Report of two cases.
Neoplasms
Fluorescence in situ hybridization as an adjunct tool in the diagnosis of primary and metastatic renal cell carcinoma in fine needle aspiration specimens.
Neoplasms
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
Neoplasms
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Neoplasms
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Neoplasms
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Neoplasms
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
Neoplasms
High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Neoplasms
High-Grade Urothelial Carcinoma of Bladder Transforming to Micropapillary Variant on Follow-Up.
Neoplasms
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Neoplasms
Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
Neoplasms
Horseradish peroxidase and aptamer dual-functionalized nanoprobe for the amplification detection of alpha-methylacyl-CoA racemase.
Neoplasms
How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
Neoplasms
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Neoplasms
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Neoplasms
Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
Neoplasms
Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.
Neoplasms
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Neoplasms
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Neoplasms
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Neoplasms
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Neoplasms
Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Neoplasms
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Neoplasms
Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney.
Neoplasms
In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.
Neoplasms
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Neoplasms
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Neoplasms
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Neoplasms
Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens.
Neoplasms
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Neoplasms
Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Neoplasms
Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.
Neoplasms
Metanephric adenoma: association between the imaging features of contrast-enhanced ultrasound and clinicopathological characteristics.
Neoplasms
Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor.
Neoplasms
Molecular diagnosis of renal cell neoplasms: the usefulness of immunohistochemistry and fluorescence in situ hybridization.
Neoplasms
Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Neoplasms
MORPHOLOGICAL DIAGNOSIS OF PANCREATIC NEUROENDOCRINE TUMORS (REVIEW AND CASE REPORT).
Neoplasms
Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
Neoplasms
Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features.
Neoplasms
Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change.
Neoplasms
New Molecular Markers for Prostate Tumor Imaging: A Study on 2-Methylene Substituted Fatty Acids as New AMACR Inhibitors.
Neoplasms
Novel 2-arylthiopropanoyl-CoA inhibitors of ?-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Neoplasms
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Neoplasms
Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course.
Neoplasms
Oncocytic renal cell carcinoma having papillotubular growth: rare morphological variant of papillary renal cell carcinoma.
Neoplasms
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.
Neoplasms
Orthotopic tumorgrafts in nude mice: A new method to study human prostate cancer.
Neoplasms
Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.
Neoplasms
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
Neoplasms
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Neoplasms
P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens.
Neoplasms
P504S: a new molecular marker for the detection of prostate carcinoma.
Neoplasms
Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Neoplasms
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Neoplasms
Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
Neoplasms
Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study.
Neoplasms
Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
Neoplasms
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Neoplasms
Phytanic acid: measurement of plasma concentrations by gas-liquid chromatography-mass spectrometry analysis and associations with diet and other plasma fatty acids.
Neoplasms
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
Neoplasms
Primary renal myxofibrosarcoma.
Neoplasms
Primary retroperitoneal renal cell carcinoma associated with transcription EB gene fusion.
Neoplasms
Primary small cell carcinoma of prostate without immunoreactive neuroendocrine proteins but with expressions of KIT and platelet-derived growth factor-?.
Neoplasms
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Neoplasms
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Neoplasms
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Neoplasms
Prostate cancer marker panel with single cell sensitivity in urine.
Neoplasms
Prostate cancer stem cells: do they have a Basal or luminal phenotype?
Neoplasms
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Neoplasms
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
Neoplasms
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Neoplasms
Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma.
Neoplasms
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Neoplasms
Renal cell carcinoma in tuberous sclerosis complex.
Neoplasms
Renal-type clear cell carcinoma of prostate: A case report and review of literature.
Neoplasms
Response to the letter by Shailendra Kapoor: AMACR is an emerging diagnostic and prognostic tool in systemic malignancies.
Neoplasms
Retroperitoneal sclerosing PEComa with melanin pigmentation and granulomatous inflammation-a rare association within an uncommon tumor.
Neoplasms
Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
Neoplasms
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Neoplasms
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Neoplasms
Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation.
Neoplasms
Semen AMACR protein as a novel method for detecting prostate cancer.
Neoplasms
Sertoli cell tumor of the testis, not otherwise specified, presenting extensive hemorrhage and overexpression of alpha-methylacyl-CoA racemase (AMACR/P504S).
Neoplasms
Sex-dependent expression of prostatic markers and hormone receptors in cystic tumor of the atrioventricular node: A histopathological study of three cases.
Neoplasms
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Neoplasms
Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
Neoplasms
Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review.
Neoplasms
Small cell neuroendocrine carcinoma of the prostate: Incidence and a report of four cases with an examination of KIT and PDGFRA.
Neoplasms
Strength of molecular cytogenetic analyses for adjusting the diagnosis of renal cell carcinomas with both clear cells and papillary features: a study of three cases.
Neoplasms
t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
Neoplasms
The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and ?-methylacyl-CoA-racemase markers.
Neoplasms
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
Neoplasms
The expressions of AMACR and iNOS in prostate adenocarcinomas.
Neoplasms
The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Neoplasms
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Neoplasms
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Neoplasms
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Neoplasms
Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review.
Neoplasms
TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Neoplasms
Tubulocystic renal cell carcinoma in the left kidney: a case report.
Neoplasms
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.
Neoplasms
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Neoplasms
Tubulocystic renal cell carcinoma: Report of a rare case.
Neoplasms
Uncommon Localization of Extrarenal Xp11.2 Translocation-associated Renal Cell Carcinoma (RCC): Case Report.
Neoplasms
Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin.
Neoplasms
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Neoplasms
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Neoplasms
Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
Neoplasms
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Neoplasms
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Neoplasms
Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Neoplasms
Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores.
Neoplasms
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Neoplasms
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Neoplasms
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Neoplasms
Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry.
Neoplasms
Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.
Neoplasms
Xp11.2 translocation renal cell carcinoma with multiple bone metastases: A case report.
Neoplasms
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
Neoplasms
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
Neoplasms
[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].
Neoplasms
[Basal-luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal transition and epithelium migration in the mesenchyme].
Neoplasms
[Clinical and morphological characteristics of thyroid tumors in children of the Chelyabinsk Region].
Neoplasms
[Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component].
Neoplasms
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]
Neoplasms
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
Neoplasms
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
Neoplasms
[Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry]
Neoplasms
[Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]
Neoplasms
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
Neoplasms
[Fatty acid synthase in the diagnosis of prostate neoplasms].
Neoplasms
[Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S]
Neoplasms
[Multi-modality MRI parameters correlate with the expression of the P504s protein in prostate cancer].
Neoplasms
[Related biomarkers in the diagnosis of prostate cancer].
Neoplasms
[Significance of P504s in distinction between solid pseudopapillary tumor of pancreas and pancreatic neuroendocrine tumors].
Neoplasms
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
Neoplasms
[Tubulocystic carcinoma of the kidney].
Neoplasms, Germ Cell and Embryonal
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Neoplasms, Glandular and Epithelial
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Neoplastic Cells, Circulating
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Nephrolithiasis
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Neuroblastoma
Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Neuroendocrine Tumors
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Neuroendocrine Tumors
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Neuroendocrine Tumors
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Neuroendocrine Tumors
[Significance of P504s in distinction between solid pseudopapillary tumor of pancreas and pancreatic neuroendocrine tumors].
Nevus
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Nevus, Pigmented
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Ovarian Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Ovarian Neoplasms
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Ovarian Neoplasms
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Paget Disease, Extramammary
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Pancreatic Neoplasms
Alpha-methylacyl-CoA racemase is expressed in a majority of pancreatic neoplasms of neuroendocrine, acinar, and solid pseudopapillary differentiation.
Papilloma
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
Papillomavirus Infections
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Parasitic Diseases
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
Peripheral Nervous System Diseases
Role of Alpha-methylacyl-CoA racemase gene in pathogenecity of CMT patients.
Peroxisomal Disorders
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Prostatic Diseases
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]
Prostatic Hyperplasia
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Prostatic Hyperplasia
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Prostatic Hyperplasia
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
Prostatic Hyperplasia
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Prostatic Hyperplasia
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
Prostatic Hyperplasia
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
Prostatic Hyperplasia
[Detection of P504S (alpha-methylacyl-CoA racemase) in prostatic adenocarcinomas]
Prostatic Intraepithelial Neoplasia
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Prostatic Intraepithelial Neoplasia
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Prostatic Intraepithelial Neoplasia
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Prostatic Intraepithelial Neoplasia
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Prostatic Intraepithelial Neoplasia
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Prostatic Intraepithelial Neoplasia
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Prostatic Intraepithelial Neoplasia
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Prostatic Intraepithelial Neoplasia
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Prostatic Intraepithelial Neoplasia
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Prostatic Intraepithelial Neoplasia
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Prostatic Intraepithelial Neoplasia
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Prostatic Intraepithelial Neoplasia
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Prostatic Intraepithelial Neoplasia
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Prostatic Intraepithelial Neoplasia
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Prostatic Intraepithelial Neoplasia
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Prostatic Intraepithelial Neoplasia
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Prostatic Intraepithelial Neoplasia
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Prostatic Intraepithelial Neoplasia
P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens.
Prostatic Intraepithelial Neoplasia
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prostatic Intraepithelial Neoplasia
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Prostatic Intraepithelial Neoplasia
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Prostatic Intraepithelial Neoplasia
Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
Prostatic Intraepithelial Neoplasia
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Prostatic Intraepithelial Neoplasia
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
Prostatic Intraepithelial Neoplasia
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
Prostatic Intraepithelial Neoplasia
[Fatty acid synthase in the diagnosis of prostate neoplasms].
Prostatic Neoplasms
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
Prostatic Neoplasms
?-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Prostatic Neoplasms
A Continuous Assay for alpha-Methylacyl-CoA Racemase (AMACR) Using Circular Dichroism.
Prostatic Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Prostatic Neoplasms
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
Prostatic Neoplasms
A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Prostatic Neoplasms
A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Prostatic Neoplasms
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
Prostatic Neoplasms
A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer.
Prostatic Neoplasms
A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Prostatic Neoplasms
Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Prostatic Neoplasms
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Prostatic Neoplasms
Abundant expression of AMACR in many distinct tumour types.
Prostatic Neoplasms
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Prostatic Neoplasms
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Prostatic Neoplasms
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Prostatic Neoplasms
Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer.
Prostatic Neoplasms
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Prostatic Neoplasms
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Prostatic Neoplasms
alpha-Methylacyl-CoA racemase (AMACR) in fine-needle aspiration specimens of prostate lesions.
Prostatic Neoplasms
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Prostatic Neoplasms
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Prostatic Neoplasms
Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
Prostatic Neoplasms
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Prostatic Neoplasms
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer.
Prostatic Neoplasms
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Prostatic Neoplasms
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
Prostatic Neoplasms
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Prostatic Neoplasms
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
Prostatic Neoplasms
Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report.
Prostatic Neoplasms
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Prostatic Neoplasms
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
Prostatic Neoplasms
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.
Prostatic Neoplasms
Bioconjugated, Single-Use Biosensor for the Detection of Biomarkers of Prostate Cancer.
Prostatic Neoplasms
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Prostatic Neoplasms
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
Prostatic Neoplasms
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Prostatic Neoplasms
Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Prostatic Neoplasms
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Prostatic Neoplasms
Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker.
Prostatic Neoplasms
Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Prostatic Neoplasms
Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.
Prostatic Neoplasms
Correlations of dietary patterns with prostate health.
Prostatic Neoplasms
Current Knowledge on the Function of ?-Methyl Acyl-CoA Racemase in Human Diseases.
Prostatic Neoplasms
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
Prostatic Neoplasms
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Prostatic Neoplasms
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Prostatic Neoplasms
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Prostatic Neoplasms
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Prostatic Neoplasms
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Prostatic Neoplasms
Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.
Prostatic Neoplasms
Diagnostic utility of ?-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer.
Prostatic Neoplasms
Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy.
Prostatic Neoplasms
Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.
Prostatic Neoplasms
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Prostatic Neoplasms
Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
Prostatic Neoplasms
Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.
Prostatic Neoplasms
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Prostatic Neoplasms
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Prostatic Neoplasms
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Prostatic Neoplasms
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Prostatic Neoplasms
Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
Prostatic Neoplasms
Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
Prostatic Neoplasms
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Prostatic Neoplasms
Endobronchial metastasis from prostate cancer mimicking primary lung cancer.
Prostatic Neoplasms
Evaluation of Combined Quantification of PCA3 and AMACR Gene Expression for Molecular Diagnosis of Prostate Cancer in Moroccan Patients by RT-qPCR
Prostatic Neoplasms
Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.
Prostatic Neoplasms
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth.
Prostatic Neoplasms
Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.
Prostatic Neoplasms
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Prostatic Neoplasms
Expression of Alpha Methylacyl CoA Racemase (AMACR) in Gastric Adenocarcinoma and Its Correlation with Helicobacter pylori Infection.
Prostatic Neoplasms
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Prostatic Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Prostatic Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Prostatic Neoplasms
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Prostatic Neoplasms
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Prostatic Neoplasms
Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
Prostatic Neoplasms
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Prostatic Neoplasms
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer.
Prostatic Neoplasms
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology.
Prostatic Neoplasms
Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
Prostatic Neoplasms
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.
Prostatic Neoplasms
Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Prostatic Neoplasms
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Prostatic Neoplasms
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Prostatic Neoplasms
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
Prostatic Neoplasms
High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Prostatic Neoplasms
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Prostatic Neoplasms
Human prostate cancer precursors and pathobiology.
Prostatic Neoplasms
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Prostatic Neoplasms
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Prostatic Neoplasms
Identification of a cell of origin for human prostate cancer.
Prostatic Neoplasms
Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.
Prostatic Neoplasms
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Prostatic Neoplasms
Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates.
Prostatic Neoplasms
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
Prostatic Neoplasms
In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Prostatic Neoplasms
Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of ?-catenin in prostate cancer cells.
Prostatic Neoplasms
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Prostatic Neoplasms
Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?
Prostatic Neoplasms
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Prostatic Neoplasms
Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.
Prostatic Neoplasms
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Prostatic Neoplasms
Lack of ERG-antibody in Benign Mimickers of Prostate Cancer.
Prostatic Neoplasms
Malignant Pleural Effusion from Metastatic Prostate Cancer: A Case Report with Unusual Cytologic Findings.
Prostatic Neoplasms
Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer.
Prostatic Neoplasms
Mn-doped ZnSe d-dots-based ?-methylacyl-CoA racemase probe for human prostate cancer cell imaging.
Prostatic Neoplasms
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.
Prostatic Neoplasms
Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter.
Prostatic Neoplasms
Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Prostatic Neoplasms
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.
Prostatic Neoplasms
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Prostatic Neoplasms
Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.
Prostatic Neoplasms
New circulating biomarkers for prostate cancer.
Prostatic Neoplasms
Novel 2-arylthiopropanoyl-CoA inhibitors of ?-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Prostatic Neoplasms
Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.
Prostatic Neoplasms
Other biomarkers for detecting prostate cancer.
Prostatic Neoplasms
p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature.
Prostatic Neoplasms
P504S expressing circulating prostate cells as a marker for prostate cancer.
Prostatic Neoplasms
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Prostatic Neoplasms
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Prostatic Neoplasms
Paneth cell-like change in benign prostate can account for P504S (AMACR) reactivity.
Prostatic Neoplasms
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
Prostatic Neoplasms
Phase-Regulated Sensing Mechanism of MoS2 Based Nanohybrids toward Point-of-Care Prostate Cancer Diagnosis.
Prostatic Neoplasms
Phytanic acid, AMACR and prostate cancer risk.
Prostatic Neoplasms
Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.
Prostatic Neoplasms
Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
Prostatic Neoplasms
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prostatic Neoplasms
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Prostatic Neoplasms
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostatic Neoplasms
Prostate carcinogenesis induced by N-methyl-N-nitrosourea (mnu) in gerbils: Histopathological diagnosis and potential invasiveness mediated by extracellular matrix components.
Prostatic Neoplasms
Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids.
Prostatic Neoplasms
PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
Prostatic Neoplasms
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Prostatic Neoplasms
Revisiting the Immunophenotype of Nephrogenic Adenoma.
Prostatic Neoplasms
RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
Prostatic Neoplasms
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Prostatic Neoplasms
Screening of differentially expressed genes and identification of AMACR as a prognostic marker in prostate cancer.
Prostatic Neoplasms
Selection of aptamers for fluorescent detection of alpha-methylacyl-CoA racemase by single-bead SELEX.
Prostatic Neoplasms
Semen AMACR protein as a novel method for detecting prostate cancer.
Prostatic Neoplasms
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Prostatic Neoplasms
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Prostatic Neoplasms
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population.
Prostatic Neoplasms
Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
Prostatic Neoplasms
Serum levels of phytanic acid are associated with prostate cancer risk.
Prostatic Neoplasms
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Prostatic Neoplasms
Significant association of alpha-methylacyl-CoA racemase gene polymorphisms with susceptibility to prostate cancer: a meta-analysis.
Prostatic Neoplasms
Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.
Prostatic Neoplasms
Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.
Prostatic Neoplasms
Suppression of ?-methylacyl-coenzyme A racemase by miR200c inhibits prostate adenocarcinoma cell proliferation and migration.
Prostatic Neoplasms
T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
Prostatic Neoplasms
The auxiliary diagnostic value of prostate-specific antigen and ?-methylacyl-CoA racemase in prostate cancer.
Prostatic Neoplasms
The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Prostatic Neoplasms
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Prostatic Neoplasms
The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer.
Prostatic Neoplasms
Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
Prostatic Neoplasms
Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane.
Prostatic Neoplasms
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Prostatic Neoplasms
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Prostatic Neoplasms
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Prostatic Neoplasms
Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Prostatic Neoplasms
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Prostatic Neoplasms
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Prostatic Neoplasms
What's new in prostate cancer disease assessment in 2006?
Prostatic Neoplasms
[An update of biomarkers in prostate cancer tissue]
Prostatic Neoplasms
[Basal-luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal transition and epithelium migration in the mesenchyme].
Prostatic Neoplasms
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
Prostatic Neoplasms
[Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
Prostatic Neoplasms
[Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]
Prostatic Neoplasms
[Histopathological features of prostate cancer]
Prostatic Neoplasms
[Immunohistochemical algorithms in prostate diagnostics : What's new?]
Prostatic Neoplasms
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Prostatic Neoplasms
[P504S and 34betaE12 dual-staining of immunohistochemistry in the diagnosis of prostate cancer]
Prostatic Neoplasms
[Related biomarkers in the diagnosis of prostate cancer].
Prostatic Neoplasms
[Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer]
Prostatitis
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications.
Refsum Disease
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Refsum Disease
The influence of the branched-chain fatty acids pristanic acid and Refsum disease-associated phytanic acid on mitochondrial functions and calcium regulation of hippocampal neurons, astrocytes, and oligodendrocytes.
Rhabdomyolysis
Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency.
Sarcoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Seizures
Phytol is lethal for Amacr-deficient mice.
Sertoli Cell Tumor
Sertoli cell tumor of the testis, not otherwise specified, presenting extensive hemorrhage and overexpression of alpha-methylacyl-CoA racemase (AMACR/P504S).
Small Cell Lung Carcinoma
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Squamous Cell Carcinoma of Head and Neck
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
Stomach Neoplasms
?-Methylacyl-CoA Racemase (AMACR) in Gastric Cancer: Correlation With Clinicopathologic Data and Disease-free Survival.
Stomach Neoplasms
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Stomach Neoplasms
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Thrombosis
?-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.
Thymoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Tremor
Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency.
Tuberculosis
A Continuous Assay for alpha-Methylacyl-CoA Racemase (AMACR) Using Circular Dichroism.
Tuberculosis
Alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis. Mutational and structural characterization of the active site and the fold.
Tuberculosis
Crystallization and preliminary X-ray diffraction studies of an alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis.
Tuberculosis
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
Tuberculosis
The catalysis of the 1,1-proton transfer by alpha-methyl-acyl-CoA racemase is coupled to a movement of the fatty acyl moiety over a hydrophobic, methionine-rich surface.
Urinary Bladder Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Urinary Bladder Neoplasms
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Vitamin K Deficiency
Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency.
Wilms Tumor
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Xanthomatosis, Cerebrotendinous
Mechanisms of disease: Inborn errors of bile acid synthesis.
Zellweger Syndrome
Mechanisms of disease: Inborn errors of bile acid synthesis.
Zellweger Syndrome
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
5.1.99.4 alpha-methylacyl-CoA racemase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
